Skip to main content

Want a detailed portfolio tracker?

Genmab (GMAB) P/E (2014 - 2026)

Genmab (GMAB) P/E from Dec 31, 2014 to Jun 3, 2026. The TTM Genmab (GMAB) P/E is 35.94. You can export chart.

All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.

P/E

Annual P/E change of Genmab (GMAB)

YearP/EChange
202635.94-18.81%
202544.27+156.94%
202417.23-50.84%
202335.05-1.49%
202235.58-36.01%
202155.61+51.22%
202036.77-18.49%
201945.11+1.33%
201844.52-27.24%
201761.19-33.85%
201692.51+28.50%
201571.99-76.14%
2014301.74N/A

Comparison Genmab (GMAB) P/E with competitors

Genmab (GMAB) P/E is 35.94.

TickerNameP/EUpside
SPRCSciSparc Ltd0.00-100.00%
NBYStablecoin Development Corp0.10-99.72%
ENLVEnlivex Therapeutics Ltd0.15-99.58%
FGENFibroGen Inc0.24-99.33%
TRAWTraws Pharma Inc0.47-98.68%
FBIOFortress Biotech Inc0.71-98.04%
CHRSCoherus Biosciences Inc0.98-97.28%
ORMPOramed Pharmaceuticals Inc1.47-95.90%
AGENAgenus Inc2.05-94.30%
VIVSVivoSim Labs Inc2.54-92.95%
INVAInnoviva Inc3.19-91.13%
CRMDCorMedix Inc3.65-89.86%
ABEOAbeona Therapeutics Inc4.20-88.30%
VXRTVaxart Inc4.26-88.14%
CVACCureVac N.V.4.45-87.63%
SRPTSarepta Therapeutics Inc4.62-87.14%
GLPGGalapagos NV4.86-86.48%
RIGLRigel Pharmaceuticals4.92-86.31%
ZVRAZevra Therapeutics Inc4.97-86.16%
ABUSArbutus Biopharma Corp5.69-84.16%
CGENCompugen Ltd7.38-79.46%
AUPHAurinia Pharmaceuticals Inc9.25-74.26%
ACADAcadia Pharmaceuticals Inc9.59-73.33%
OMEROmeros Corporation9.88-72.50%
PLXProtalix BioTherapeutics Inc9.91-72.43%
SPROSpero Therapeutics Inc10.73-70.13%
ADMAAdma Biologics Inc11.33-68.48%
SVASinovac Biotech Ltd11.44-68.18%
TBPHTheravance Biopharma Inc11.78-67.24%
HRMYHarmony Biosciences Holdings Inc12.18-66.11%
TGTXTG Therapeutics Inc13.18-63.33%
INCYIncyte Corp13.38-62.77%
SABSSAB Biotherapeutics Inc14.06-60.89%
XOMAXOMA Corp14.95-58.42%
REGNRegeneron Pharmaceuticals Inc14.98-58.32%
PBYIPuma Biotechnology Inc15.05-58.13%
EXELExelixis Inc15.79-56.06%
NAGENiagen Bioscience Inc16.35-54.50%
CPRXCatalyst Pharmaceuticals Inc17.34-51.74%
MDXGMimedx Group Inc17.38-51.66%
ARGXArgen X SE23.07-35.81%
HALOHalozyme Therapeutics Inc23.20-35.45%
XOMAOXOMA Corp25.34-29.49%
VRTXVertex Pharmaceuticals Inc25.66-28.62%
XOMAPXOMA Corp25.67-28.58%
CTMXCytomX Therapeutics Inc25.70-28.51%
ASNDAscendis Pharma A/S26.35-26.68%
RPRXRoyalty Pharma plc - Class A27.50-23.50%
SLNOSoleno Therapeutics Inc29.02-19.28%
LGNDLigand Pharmaceuticals Inc - Class B30.19-16.02%
BMRNBiomarin Pharmaceutical Inc37.51+4.35%
APLSApellis Pharmaceuticals Inc39.02+8.56%
KRYSKrystal Biotech Inc39.70+10.44%
ONCBeiGene Ltd67.03+86.48%
TECHBio-Techne Corp68.59+90.84%
VCELVericel Corp80.63+124.32%
PHARPharming Group N.V.87.74+144.10%
ALNYAlnylam Pharmaceuticals Inc124.93+247.58%
TLXTelix Pharmaceuticals Ltd139.89+289.19%
CORTCorcept Therapeutics Inc158.39+340.66%